Archives for: ‘Kim O’Connell’

United States Court of Appeals upholds PTAB decision on CRISPR Patent Interference

The interference action between the University of California (UC) and Broad Institute (Broad) has seemingly come to an end, with the United States Court of Appeals for the Federal Circuit Court (CAFC) affirming that the patent claims that had been granted to Broad in relation to its CRISPR/Cas9 gene editing patents are separately patentable from the claims of a patent application made by UC.

Read More
Subjects:

United States FDA gets serious about biosimilars

The most significant advances in medical treatments are being made with biological products.  As biological medicines are significantly more expensive than traditional small molecule drugs, upward pressure is being placed on health spending. For example, in the United States, biological medicines accounted for 40% of all prescription drugs spending and 70% of the increase in healthcare spending in the five …

Read More
Subjects:

Digital health receives funding boost from Federal Government

Australia’s digital health sector received a major boost in April this year when the Federal Government announced a $55 million cash injection to launch the new Digital Health Cooperative Research Centre (CRC) and its programs which will bring together a consortium of more than 60 health, medical technology and pharmaceutical companies, universities and research institutes operating across the health, aged …

Read More
Subjects:

Australian Plant Breeders’ Rights to be significantly strengthened

The Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Bill 2018 seeks to introduce yet further changes aimed at improving Australia’s intellectual property laws.  The proposed amendments to the Plant Breeder’s Rights Act, 1994 cover many key aspects of Australia’s plant breeders’ rights regime and are expected to have a significant impact on the agricultural sector.  For …

Read More

#BIO2018: Gene therapy, AI in healthcare, precision medicine and Diana Ross – The power of biotechnology

As we wrap up our week of insights on the biotech industry and coverage of #Bio2018, what is clear is that for many biotech innovations, the story is just beginning. From landmark developments in genetic engineering techniques, the integration of AI and digital technologies into health care products and services and the increasing investment in genomics based medicine, perhaps the …

Read More
Subjects:

Gene editing and genetic engineering techniques

Continuing our series on biotechnology for #Bio2018, this post looks at the development of new gene editing and genetic engineering techniques – a key trend shaping the biotechnology industry.   New genome editing techniques, such as CRISPR/Cas9, have made editing genomic material cheap, efficient and accessible.  These new techniques have opened up a plethora of opportunities for scientific progress previously considered …

Read More
Subjects:

#BIO2018: KWM report from the Bio 2018 Convention

Couldn’t make it to #Bio2018? This week, Anna Feros reports on her insights from the BIO International Convention in Boston, hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations.  The first full day at BIO2018 kicked off with an inspirational keynote session led by BIO president, Jim Greenwood, who …

Read More
Subjects:

How AI is shaping healthcare

As keepers of the world’s ‘big data’, many of the major tech companies  are naturally well placed to turn to the data-hungry development of artificial intelligence, or AI.  And while AI is a hot topic in almost every industry, its presence and potential application in healthcare is exploding. AI – what is it exactly? In the simplest sense, AI is …

Read More
Subjects: | |

The final word and ‘smoking gun’ documents – ACCC v Pfizer

For those readers interested in the issues surrounding competitive moves by pharmaceutical companies in the scenario where a key patent comes to an end, we report on the recent decision of the Full Federal Court in the ACCC v Pfizer matter here: ACCC v Pfizer – KWM News & Insights

Read More

Page 1 of 2112345»1020...Last »